MAC.22 (TMIST) screening for breast cancer with tomosynthesis mammography Wednesday, May 23, 2018 The Sunnybrook Health Sciences Centre and the Ottawa Hospital are currently enrolling women in the Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare conventional mammography (2-D) to the newer digital tomosynthesis method (3-D).The large scale North American study was developed by the US based ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) and the National Cancer Institute (NCI), with the Canadian Cancer Trials Group (CCTG) coordinating the trial in Canada (more national sites will be opening the trial over the next several months). Read more For more information about the trial please contact: CCTG MAC.22 Study Coordinators: WenLing Liu Dora Baczyk
